Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial

Yoshiaki Oda; Yuji Kumagai; Manabu Kanai; Yasuhiro Iwama; Iori Okura; Takeshi Minamida; Yukihiro Yagi; Toru Kurosawa; Benjamin N. Greener; Ye Zhang; Judd L. Walson

doi:10.1016/s1473-3099(23)00650-3

Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial

著者: Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Benjamin N. Greener, Ye Zhang, Judd L. Walson - The Lancet 2023 被引用: 119

Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial | Litlas